Utility of Caspase-Cleaved Keratin 18 to Diagnose NASH in Patients with Obesity

NASH and all its complications are especially prevalent in patients with severe obesity and type 2 diabetes. Yet few study data exist on biomarker performance within this patient group, in order to move away from the necessity of liver biopsy in clinical practice.

Sami Qadri, MD & Hannele Yki-Järvinen, MD et al. performed a study to evaluate the use of the M30 Apoptosense ELISA® to diagnose NASH or fibrotic NASH in an obese cohort.

They found that plasma levels of M30® associated with the full histological spectrum of NASH and also had a good ability to identify both NASH and fibrotic NASH with high sensitivity and specificity!

Click here to access the full White Paper!